ArticleAmerican journal of cancer research2022

Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer.

Lorenzo Fornaro et al.PubMed ↗Full text ↗

No numbers read from the abstract.